English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA preclinical study led by a faculty member at Roswell Park Comprehensive Cancer Center shows that gilteritinib (brand name Xospata), a targeted cancer treatment, can strengthen chimeric antigen receptor (CAR) T-cell immunotherapy in two high-risk pediatric leukemias that have poor survival rates — FLT3-mutated acute myeloid leukemia (AML) and KMT2A-rearranged acute lymphoblastic leukemia (ALL). Lisa Niswander, MD, PhD, Assistant Professor of Oncology in the Department of Pediatric Oncology, will deliver the results this afternoon in an oral abstract session at the 66th annual meeting of the American Society of Hematology (ASH) in San Diego, California.
Tag: pediatric leukemia
Age impacts pharmacogenomics and treatment outcomes for most common form of leukemia
Explore how scientists at St. Jude Children’s Research Hospital have identified causes for age-related differences in treatment outcomes of B-cell acute lymphoblastic leukemia.
New NCCN Resource for Understanding Childhood Leukemia
NCCN publishes a new patient and caregiver resource focused on a childhood cancer type. Free NCCN Guidelines for Patients: Pediatric Acute Lymphoblastic Leukemia (ALL) shares the latest expert advice for treating infants, children, and adolescents with the most common pediatric malignancy.